1344700-45-3

Upstream product

• 1344700-01-1 N,N²,O-trimethyl-3-oxoserinamide hydrochloride 
• 1344700-00-0 N²-(t-butoxycarbonyl)-N,N²,O-trimethyl-3-oxoserinamide 
• 36295-63-3 diethyl 2-(methylamino)propanedioate 
• 1344699-99-5 diethyl [(t-butoxycarbonyl)(methyl)amino]propanedioate 
• 1344699-98-4 ({[1-methoxy-3-(methylamino)-1,3-dioxopropan-2-yl](methyl)amino}methyl)benzene 
• 5417-21-0 dimethyl [benzyl(methyl)amino]propanedioate 
• 1032-02-6 diethyl 2-(benzyl(methyl)amino)propanedioate 
• 63697-96-1 4-Ethynylbenzaldehyde 
• 51934-41-9 4-iodobenzoic acid ethyl ester 
• 1344700-43-1 1-(dimethoxymethyl)-4-[(4-{[1-methoxy-3-(methylamino)-1,3-dioxopropan-2-yl](methyl)carbamoyl}phenyl)ethynyl]benzene 
• 1344700-42-0 4-{[4-(dimethoxymethyl)phenyl]ethynyl}benzoic acid 
• 1344700-41-9 ethyl 4-{[4-(dimethoxymethyl)phenyl]ethynyl}benzoate 
• 1344700-44-2 1-formyl-4-[(4-{[1-methoxy-3-(methylamino)-1,3-dioxopropan-2-yl](methyl)carbamoyl}phenyl)ethynyl]benzene 
• 765-30-0 Cyclopropylamine 

Relevant academic research and scientific papers

NOVEL HYDROXAMIC ACID DERIVATIVE

Provided is a novel compound which is useful as a pharmaceutical composition by inhibiting an LpxC activity, thereby exhibiting potent antimicrobial activity against gram-negative bacteria including Pseudomonas aeruginosa and its drug resistant bacteria. Provided is a hydroxamic acid derivative represented by the following general formula [1] or a pharmaceutically acceptable salt thereof: